290 results on '"Germing U"'
Search Results
2. Response-guided first-line therapy and treatment of relapse in aggressive lymphoma: 10-year follow-up of the PETAL trial
3. Monocytosis at the time of diagnosis has a negative prognostic impact in myelodysplastic syndromes with less than 5% bone marrow blasts
4. Therapy-related myeloid neoplasms following treatment for multiple myeloma—a single center analysis
5. The WHO 2016 diagnostic criteria for Acute Myeloid leukemia with myelodysplasia related changes (AML-MRC) produce a very heterogeneous entity: A retrospective analysis of the FAB subtype RAEB-T
6. Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification—an approach to classification of patients with t-MDS
7. Analysis of the impact of adherence to guidelines and expert advice in patients with myelodysplastic syndromes
8. Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials
9. The IPSS-R has prognostic impact in untreated patients with MDS del(5q)
10. Myelodysplastic syndromes without peripheral monocytosis but with evidence of marrow monocytosis share clinical and molecular characteristics with CMML
11. Refined medullary blast and white blood cell count based classification of chronic myelomonocytic leukemias
12. Functional inhibition of mesenchymal stromal cells in acute myeloid leukemia
13. Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM)
14. Serum CD44 levels predict survival in patients with low-risk myelodysplastic syndromes
15. Distinguishing myelodysplastic syndromes (MDS) from idiopathic cytopenia of undetermined significance (ICUS): HUMARA unravels clonality in a subgroup of patients
16. A 3-day short course of palifermin before HDT reduces toxicity and need for supportive care after autologous blood stem-cell transplantation in patients with multiple myeloma
17. Prognostic impact of age and gender in 897 untreated patients with primary myelodysplastic syndromes
18. Reply to ‘Allogeneic hematopoietic cell transplantation for concurrent multiple myeloma and myelodysplastic syndromeʼ
19. Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM)
20. Tigecycline in febrile neutropenic patients with haematological malignancies: a retrospective case documentation in four university hospitals
21. Prognostic impact of blast cell counts in dysplastic bone marrow disorders (MDS and CMML I) with concomitant fibrosis
22. Monosomal karyotype in MDS: explaining the poor prognosis?
23. Age, JAK2V617F and SF3B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts and marked thrombocytosis
24. Insufficient stromal support in MDS results from molecular and functional deficits of mesenchymal stromal cells
25. Beurteilung myeloischer und lymphatischer Neoplasien bei beruflicher Benzolexposition
26. Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation
27. Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): A multicenter study
28. Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q
29. 5-Azacytidine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome who relapse after allo-SCT: a retrospective analysis
30. Low rate of calreticulin mutations in refractory anaemia with ring sideroblasts and marked thrombocytosis
31. Phase 2 study of oral panobinostat (LBH589) with or without erythropoietin in heavily transfusion-dependent IPSS low or int-1 MDS patients
32. Low IPSS score and bone marrow hypocellularity in MDS patients predict hematological responses to antithymocyte globulin
33. Improvement of criteria for refractory cytopenia with multilineage dysplasia according to the WHO classification based on prognostic significance of morphological features in patients with refractory anemia according to the FAB classification
34. Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS)
35. Quantification of outpatient management and hospitalization of patients with high-risk myelodysplastic syndrome treated with low-dose decitabine
36. Splenektomie bei idiopathischer thrombozytopenischer Purpura: Retrospektive Analyse des postoperativen Verlaufs
37. High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemia
38. Cyclosporine A and Mycophenolate Mofetil vs Cyclosporine A and Methotrexate for graft-versus-host disease prophylaxis after stem cell transplantation from HLA-identical siblings
39. A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes
40. Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31
41. The emergence of a C/EBPα mutation in the clonal evolution of MDS towards secondary AML
42. Salvage therapy with azacitidine increases regulatory T cells in peripheral blood of patients with AML or MDS and early relapse after allogeneic blood stem cell transplantation
43. Combination of Azacitidine and Lenalidomide in Myelodysplastic Syndromes or acute Myeloid Leukemia—a wise Liaison?
44. Activation of the mTOR signaling pathway by L-leucine in 5q- syndrome and other RPS14-deficient erythroblasts
45. Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study
46. Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis
47. Bildgebende Diagnostik supradiaphragmaler Manifestationen extranodaler Non-Hodgkin-Lymphome
48. Evaluating the prognosis of patients with myelodysplastic syndromes
49. Testicular infiltration in acute myeloid leukemia with complex karyotype including t(8;21)
50. Thalidomide for the treatment of patients with myelodysplastic syndromes
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.